Inspection Record
View the regulator's official source The source document is always the basis for judgement.
Marketing of a product, potassium iodide capsules of 65 mg equivalent to 50 mg iodine, which does not have a Marketing Authorization issued by NAMMDR. Action taken/proposed by the NCA: Suspension of the manufacturing authorisation No. 56F in Full Withdrawal, of current valid GMP certificate No. 009/2018/RO withdrawal of current valid GMP Certificate no.009/2018/RO
Extracted automatically from the document EMA (Europe) published on 2023-03-22. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.
Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.
Click the confirmation button in the email. It's sent from GRM Solutions Brief. If you don't see it, check your spam folder.
Growth stages previewSolve a quiz to start hatching
Your growth record is stored safely in this browser.
